Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dinaciclib - Merck & Co

Drug Profile

Dinaciclib - Merck & Co

Alternative Names: MK-7965; PS-095760; SCH 727965; SCHOOL 727965

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacopeia
  • Developer AbbVie; Merck & Co; University of California at San Francisco
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase I Acute myeloid leukaemia; Breast cancer; Haematological malignancies
  • No development reported Non-small cell lung cancer
  • Discontinued Leukaemia; Mantle-cell lymphoma

Most Recent Events

  • 23 Jul 2018 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain (IV) (NCT03484520)
  • 24 Jun 2018 Biomarkers information updated
  • 06 Apr 2018 AbbVie in collaboration with Merck Sharp & Dohme plans a phase Ib trial in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in USA and Australia, in June 2018 (NCT03484520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top